Your browser doesn't support javascript.
loading
Determination and Management of Risks for Practices and Procedures in the Elderly (DRIPP): the impact of a comprehensive geriatric evaluation in elderly with diffuse large B-cell lymphoma.
Warley, Fernando; Kalmus, Mariana; Cristaldo, Nancy; Otero, Victoria; Ismael, Ileana L; Boietti, Bruno; Smietniansky, Maximiliano.
Afiliación
  • Warley F; Hematology Section, Internal Medicine Department, Hospital Italiano de Bueno Aires, Argentina. Electronic address: ferwarley@gmail.com.
  • Kalmus M; Hematology Section, Internal Medicine Department, Hospital Italiano de Bueno Aires, Argentina.
  • Cristaldo N; Hematology Section, Internal Medicine Department, Hospital Italiano de Bueno Aires, Argentina.
  • Otero V; Hematology Section, Internal Medicine Department, Hospital Italiano de Bueno Aires, Argentina.
  • Ismael IL; University Institute Hospital Italiano de Buenos Aires, Argentina.
  • Boietti B; University Institute Hospital Italiano de Buenos Aires, Argentina.
  • Smietniansky M; Geriatric section, Internal Medicine Department, Hospital Italiano de Buenos Aires, Argentina; DRIPP program coordinator, Buenos Aires, Argentina.
Hematol Transfus Cell Ther ; 2023 Nov 29.
Article en En | MEDLINE | ID: mdl-38307825
ABSTRACT

INTRODUCTION:

Diffuse large B-cell lymphoma (DLBCL) treatment in older patients is challenging. The Determination and Management of Risks for Practices and Procedures in the Elderly (DRIPP) is a multidimensional evaluation program that involves patients undergoing oncological treatments.

OBJECTIVE:

We aimed to evaluate the overall survival and progression-free survival (PFS) of patients evaluated and those not evaluated by the DRIPP. MATERIALS AND

METHODS:

Retrospective cohort study, patients > 65 years with DLBCL were included. They were divided into 3 groups patients with a diagnosis prior to the DRIPP implementation (pre-DRIPP), patients with the DRIPP (DRIPP) and patients with a diagnosis after the DRIPP implementation, but who did not undergo the evaluation (non-DRIPP).

RESULTS:

A total of 125 patients were analyzed. Fourteen (11%) patients in the pre-DRIPP group, 74 (59%) in the DRIPP group, and 37 (30%) in the non-DRIPP group. In 43 (58%) patients of the DRIPP group, some drug dose adjustments were made vs. 19 (15%) in the non-DRIPP (p = 0.03). There were no significant differences in terms of discontinuation of treatment or hematological toxicity between groups. The OS and PFS in one year was 64% (95%CI 34-83) and 50% (95%CI 23-72) for the pre-DRIPP group, 82% (95%CI 71-89) and 72% (95%CI 60-81) for the DRIPP group, 58% (95% CI 41-72) and 56% (95% CI 38-70) for the non-DRIPP group, (p = 0.08). The analysis was adjusted for probable confounders and no differences were found.

CONCLUSIONS:

This is the first study to evaluate the DRIPP as a decision-making tool in patients with lymphoma and showed a trend towards improvement in the OS in evaluated patients.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Etiology_studies / Observational_studies / Risk_factors_studies Idioma: En Revista: Hematol Transfus Cell Ther Año: 2023 Tipo del documento: Article Pais de publicación: Brasil
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Etiology_studies / Observational_studies / Risk_factors_studies Idioma: En Revista: Hematol Transfus Cell Ther Año: 2023 Tipo del documento: Article Pais de publicación: Brasil